The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to c
The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to c
Tune in for insights on:The convergence of senior healthcare and housing—and implications for healthcare REITs and private equity professionalsThe operational and hospitality components that make senior housing and skilled nursing facilities a
Tune in for insights on:The convergence of senior healthcare and housing—and implications for healthcare REITs and private equity professionalsThe operational and hospitality components that make senior housing and skilled nursing facilities a
Seniors—the fastest-growing U.S. age demographic—are poised to make up more than 20 percent of the U.S. population by 2029. And they’re moving to the driver’s seat of care. Now, they’re demanding elder care more rooted in empathy and designed o
Seniors—the fastest-growing U.S. age demographic—are poised to make up more than 20 percent of the U.S. population by 2029. And they’re moving to the driver’s seat of care. Now, they’re demanding elder care more rooted in empathy and designed o
With KKR's $10 billion purchase of Envision Healthcare this summer, the largest healthcare buyout deal since the financial crisis, private equity's appetite for healthcare deals might well be stronger than ever. Meanwhile, with Amazon's emergin
With KKR's $10 billion purchase of Envision Healthcare this summer, the largest healthcare buyout deal since the financial crisis, private equity's appetite for healthcare deals might well be stronger than ever. Meanwhile, with Amazon's emergin
Dr. David Friend, managing director and chief transformation officer of the BDO Center for Healthcare Excellence and Innovation talks about developing models and measurements for value-based care as a method to lower drug prices with Ann Kraft,
Tune in to the full episode to hear about:Why industry outsiders are entering healthcareHow these outsiders are uniquely suited to improve customer service and lower costsWhat business strategies have the most potential to create growth
Tune in to the full episode to hear about:Why industry outsiders are entering healthcareHow these outsiders are uniquely suited to improve customer service and lower costsWhat business strategies have the most potential to create growth
Tune in to the full episode to hear about:The exponential growth in genetic testing and genomic technologiesNew drug therapies that are based on live organismsInnovation in technology platforms connecting patients, providers, payers, industry,
Tune in to the full episode to hear about:The exponential growth in genetic testing and genomic technologiesNew drug therapies that are based on live organismsInnovation in technology platforms connecting patients, providers, payers, industry,